{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T22:56:33Z","timestamp":1791327393853,"version":"4.3.1"},"reference-count":36,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2015,7,1]],"date-time":"2015-07-01T00:00:00Z","timestamp":1435708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2015,7]]},"DOI":"10.1016\/j.ygyno.2015.04.006","type":"journal-article","created":{"date-parts":[[2015,4,15]],"date-time":"2015-04-15T21:15:18Z","timestamp":1429132518000},"page":"24-29","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"title":["Phase II evaluation of dalantercept, a soluble recombinant activin receptor-like kinase 1 (ALK1) receptor fusion protein, for the treatment of recurrent or persistent endometrial cancer: An NRG Oncology\/Gynecologic Oncology Group Study 0229N"],"prefix":"10.1016","volume":"138","clinical-trial-number":[{"clinical-trial-number":"nct01458392","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01720173","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01727336","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02024087","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Vicky","family":"Makker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia L.","family":"Filiaci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee-may","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Darus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James E.","family":"Kendrick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Sutton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Moxley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol","family":"Aghajanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2015.04.006_bb0005","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3322\/caac.21208","article-title":"Cancer statistics, 2014","volume":"64","author":"Siegel","year":"2014","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ygyno.2015.04.006_bb0010","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.ygyno.2012.03.034","article-title":"Randomized phase III noninferiority trial of first line chemotherapy for metastatic or recurrent endometrial carcinoma: a Gynecologic Oncology Group study","volume":"125","author":"Miller","year":"2012","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2015.04.006_bb0015","doi-asserted-by":"crossref","first-page":"2360","DOI":"10.1200\/JCO.2002.08.171","article-title":"Phase II trial of the pegylated liposomal doxorubicin in previously treated metastatic endometrial cancer: a Gynecologic Oncology Group study","volume":"20","author":"Muggia","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2015.04.006_bb0020","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1006\/gyno.2002.6804","article-title":"A phase II trial of topotecan in patients with advanced, persistent, or recurrent endometrial carcinoma: a gynecologic oncology group study","volume":"87","author":"Miller","year":"2002","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2015.04.006_bb0025","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ygyno.2008.06.013","article-title":"A phase II evaluation of weekly docetaxel in the treatment of recurrent or persistent endometrial carcinoma: a study by the Gynecologic Oncology Group","volume":"111","author":"Garcia","year":"2008","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2015.04.006_bb0030","doi-asserted-by":"crossref","first-page":"3104","DOI":"10.1200\/JCO.2008.20.6995","article-title":"Phase II trial of ixabepilone as second-line treatment in advanced endometrial cancer: gynecologic oncology group trial 129-P","volume":"27","author":"Dizon","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2015.04.006_bb0035","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.ygyno.2009.09.004","article-title":"A phase II evaluation of pemetrexed (Alimta, LY231514, IND #40061) in the treatment of recurrent or persistent endometrial carcinoma: a phase II study of the Gynecologic Oncology","volume":"115","author":"Miller","year":"2009","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2015.04.006_bb0040","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.ygyno.2010.11.027","article-title":"A phase II study of gemcitabine (Gemzar, LY188011) in the treatment of recurrent or persistent endometrial carcinoma: a gynecologic oncology group study","volume":"121","author":"Tait","year":"2011","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2015.04.006_bb0045","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S0090-8258(02)00068-9","article-title":"Activity of paclitaxel as second-line chemotherapy in endometrial carcinoma: a gynecologic oncology group study","volume":"88","author":"Lincoln","year":"2003","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2015.04.006_bb0050","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.ygyno.2007.01.019","article-title":"A phase II trial of thalidomide in patients with refractory endometrial cancer and correlation with angiogenesis biomarkers: a Gynecologic Oncology Group study","volume":"105","author":"McMeekin","year":"2007","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2015.04.006_bb0055","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.ygyno.2013.02.019","article-title":"A phase II evaluation of gefitinib in the treatment of persistent or recurrent endometrial cancer: a Gynecologic Oncology Group study","volume":"129","author":"Leslie","year":"2013","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2015.04.006_bb0060","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.ygyno.2012.07.127","article-title":"Lapatinib and potential prognostic value of EGFR mutations in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancer","volume":"127","author":"Leslie","year":"2012","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2015.04.006_bb0065","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1200\/JCO.2010.32.6397","article-title":"A phase II evaluation of bevacizumab in the treatment of recurrent or persistent endometrial cancer: a Gynecologic Oncology Group (GOG) study","volume":"29","author":"Aghajanian","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2015.04.006_bb0070","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.ygyno.2012.08.020","article-title":"A phase II evaluation of aflibercept in the treatment of recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study","volume":"127","author":"Coleman","year":"2012","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2015.04.006_bb0075","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ygyno.2012.12.022","article-title":"Phase II trial of combination bevacizumab and temsirolimus in the treatment of recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study","volume":"129","author":"Alvarez","year":"2013","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2015.04.006_bb0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.ygyno.2013.04.007","article-title":"A phase II evaluation of AZD6244, a selective MEK-1\/2 inhibitor in the treatment of recurrent or persistent endometrial cancer: a Gynecologic Oncology Group Study","author":"Coleman","year":"2013","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2015.04.006_bb0085","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ygyno.2014.07.083","article-title":"A phase II trial of brivanib in recurrent or persistent endometrial carcinoma: an NRG Oncology\/Gynecologic Oncology Group Study","volume":"135","author":"Powell","year":"2014","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2015.04.006_bb0090","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ygyno.2014.03.153","article-title":"Results of 229K: a phase II trial of BIBF-1120 for women with advanced, recurrent, or metastatic endometrial carcinoma: a Gynecologic Oncology Group study","volume":"133","author":"Dizon","year":"2014","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2015.04.006_bb0095","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1242\/dev.01094","article-title":"BMP10 is essential for maintaining cardiac growth during murine cardiogenesis","volume":"131","author":"Chen","year":"2004","journal-title":"Development"},{"key":"10.1016\/j.ygyno.2015.04.006_bb0100","doi-asserted-by":"crossref","first-page":"2626","DOI":"10.1073\/pnas.97.6.2626","article-title":"Activin receptor-like kinase 1 modulates transforming growth factor-b1 signaling in the regulation of angiogenesis","volume":"97","author":"Oh","year":"2000","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.ygyno.2015.04.006_bb0105","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0092-8674(03)00432-X","article-title":"Mechanisms of TGF-beta signaling from cell membrane to the nucleus","volume":"113","author":"Shi","year":"2003","journal-title":"Cell"},{"key":"10.1016\/j.ygyno.2015.04.006_bb0110","doi-asserted-by":"crossref","first-page":"6999","DOI":"10.1182\/blood-2011-01-330142","article-title":"ALK1 as an emerging target for antiangiogenic therapy of cancer","volume":"117","author":"Cunha","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.ygyno.2015.04.006_bb0115","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","article-title":"The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data","volume":"2","author":"Cerami","year":"2012","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ygyno.2015.04.006_bb0120","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1158\/1078-0432.CCR-13-1840","article-title":"Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of dalantercept, an activin receptor-like kinase-1 ligand trap, in patients with advanced cancer","volume":"20","author":"Bendell","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2015.04.006_bb0125","doi-asserted-by":"crossref","first-page":"3493","DOI":"10.1074\/jbc.M406613200","article-title":"A novel role for vascular endothelial growth factor as an autocrine survival factor for embryonic stem cells during hypoxia","volume":"280","author":"Brusselmans","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ygyno.2015.04.006_bb0130","doi-asserted-by":"crossref","first-page":"277","DOI":"10.2147\/vhrm.2005.1.4.277","article-title":"Pathophysiology of tumor neovascularization","volume":"1","author":"Furuya","year":"2005","journal-title":"Vasc. Health Risk Manag."},{"key":"10.1016\/j.ygyno.2015.04.006_bb0135","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1177\/1740774512450101","article-title":"A method for utilizing co-primary efficacy outcome measures to screen regimens for activity in two-stage Phase II clinical trials","volume":"9","author":"Sill","year":"2012","journal-title":"Clin. Trials"},{"key":"10.1016\/j.ygyno.2015.04.006_bb0140","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1093\/biomet\/26.4.404","article-title":"The use of confidence or fiducial limits illustrated in the case of the binomial","volume":"26","author":"Clopper","year":"1934","journal-title":"Biometrika"},{"key":"10.1016\/j.ygyno.2015.04.006_bb0145","doi-asserted-by":"crossref","first-page":"29","DOI":"10.2307\/2530286","article-title":"A confidence interval for the median survival time","volume":"38","author":"Brookmeyer","year":"1982","journal-title":"Biometrics"},{"key":"10.1016\/j.ygyno.2015.04.006_bb0150","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.ygyno.2015.04.006_bb0155","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1159\/000085589","article-title":"VEGF and its receptors (flt-1 and KDR\/flk-1) as prognostic indicators in endometrial carcinoma","volume":"26","author":"Talvensaari-Mattila","year":"2005","journal-title":"Tumour Biol."},{"key":"10.1016\/j.ygyno.2015.04.006_bb0160","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1111\/j.1440-1827.2006.02071.x","article-title":"Angiogenic factors in normal endometrium and endometrial adenocarcinoma","volume":"57","author":"Saito","year":"2007","journal-title":"Pathol. Int."},{"key":"10.1016\/j.ygyno.2015.04.006_bb0165","first-page":"1361","article-title":"Expression of vascular endothelial growth factor (VEGF)-D and its receptor, VEGF receptor 3, as a prognostic factor in endometrial carcinoma","volume":"9","author":"Yokoyama","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2015.04.006_bb0170","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1002\/1097-0142(20011115)92:10<2569::AID-CNCR1609>3.0.CO;2-3","article-title":"The angiogenic \u201cvascular endothelial growth factor\/flk-1(KDR) receptor\u201d pathway in patients with endometrial carcinoma: prognostic and therapeutic implications","volume":"92","author":"Giatromanolaki","year":"2001","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2015.04.006_bb0175","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1006\/gyno.2000.6056","article-title":"Expression of vascular endothelial growth factors (VEGF-A\/VEGF-1 and VEGF-C\/VEGF-2) in postmenopausal uterine endometrial carcinoma","volume":"80","author":"Hirai","year":"2001","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2015.04.006_bb0180","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/modpathol.3800579","article-title":"Tumour and Angiogenesis Research Group. Phosphorylated KDR expression in endometrial cancer cells relates to HIF1alpha\/VEGF pathway and unfavorable prognosis","volume":"19","author":"Giatromanolaki","year":"2006","journal-title":"Mod. Pathol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825815007969?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825815007969?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,23]],"date-time":"2018-09-23T09:26:17Z","timestamp":1537694777000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825815007969"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,7]]}},"alternative-id":["S0090825815007969"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2015.04.006","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2015,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase II evaluation of dalantercept, a soluble recombinant activin receptor-like kinase 1 (ALK1) receptor fusion protein, for the treatment of recurrent or persistent endometrial cancer: An NRG Oncology\/Gynecologic Oncology Group Study 0229N","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2015.04.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}